Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
Guardant Health received FDA approval for its Guardant360 CDx test as a companion diagnostic for Arvinas and Pfizer’s VEPPANU in ER+/HER2- advanced breast cancer. The blood-based test identifies patients with ESR1 mutations eligible for the new PROTAC therapy, representing the third ESR1 companion diagnostic approval for Guardant.
Key figures
- Covered lives
- 300000000
- Esr1 companion diagnostics
- 3
- Companion diagnostic indications
- 26
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.